Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Non-Current Assets: 2023-2025

Historic Other Non-Current Assets for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $266,000.

  • Contineum Therapeutics' Other Non-Current Assets rose 8766.67% to $266,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $266,000, marking a year-over-year increase of 8766.67%. This contributed to the annual value of $3,000 for FY2024, which is 99.77% down from last year.
  • Latest data reveals that Contineum Therapeutics reported Other Non-Current Assets of $266,000 as of Q3 2025, which was up 43.01% from $186,000 recorded in Q2 2025.
  • Contineum Therapeutics' Other Non-Current Assets' 5-year high stood at $2.6 million during Q1 2024, with a 5-year trough of $3,000 in Q2 2024.
  • Its 3-year average for Other Non-Current Assets is $546,375, with a median of $95,000 in 2025.
  • The largest annual percentage gain for Contineum Therapeutics' Other Non-Current Assets in the last 5 years was 8,766.67% (2025), contrasted with its biggest fall of 99.85% (2025).
  • Contineum Therapeutics' Other Non-Current Assets (Quarterly) stood at $1.3 million in 2023, then crashed by 99.77% to $3,000 in 2024, then surged by 8,766.67% to $266,000 in 2025.
  • Its Other Non-Current Assets was $266,000 in Q3 2025, compared to $186,000 in Q2 2025 and $4,000 in Q1 2025.